T
T3D Therapeutics
A company developing remedial therapeutics for Alzheimer's disease and other CNS disorders
About T3D Therapeutics
T3D Therapeutics, Inc., founded in 2013, is a biopharmaceutical company focused on developing transformative treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company's flagship product, T3D-959, is a novel drug candidate designed to modify the course of Alzheimer's and related neurodegenerative diseases by improving multiple defects caused by these conditions. T3D-959 aims to enhance memory, motor function, and cognition, addressing the high energy metabolism needs of the brain, which uses a significant portion of the body's glucose and oxygen. T3D Therapeutics operates in the healthcare and pharmaceutical market, targeting patients with mild to moderate Alzheimer's disease. The company generates revenue through the development and potential commercialization of its drug candidates. By participating in clinical trials and securing partnerships, T3D Therapeutics aims to bring its innovative treatments to market, offering new hope for patients and caregivers affected by neurodegenerative diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Durham, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 58.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Alzheimers Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Sep 2022 | $6M | $75M | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Nov 2019 | $15M | $60M | National Institute on Aging · National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for T3D Therapeutics is 1.8K monthly website visits, up 127.8% over the last three months. T3D Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
National Institute on Aging
National Institutes of Health
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about T3D Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See T3D Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.